At a glance
ClinicalIndex Comparison RecordPhase 2Active· 10 enrolled
Drug / intervention
Tazemetostatdrug
Likely dose
Tazemetostat 520 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
In Brief
A Phase 2 clinical trial evaluating Tazemetostat for Peripheral Nerve Sheath Tumor. Active but no longer recruiting, targeting 10 participants across 1 site.
Detailed Summary
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Nerve Sheath Tumor
CountriesUnited States
CollaboratorsEpizyme, Inc.
Timeline
Phase 2Active
202220232024202520262027
First PostedJun 2021
Enrollment StartAug 2021
Primary CompletionFeb 2025
TodayJul 2026
Study CompletionDec 2026
First PostedJun 8, 2021
Enrollment StartAug 25, 2021
Primary CompletionFeb 14, 2025
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.1 years ago
Interventions
Tazemetostatdrug
Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.